Why ? 1. Very low Valuation versus all peers is amazingly 1/10th...

Why ?

1. Very low Valuation versus all peers is amazingly 1/10th of MMJ, MXC, AC8,

and 1/5 of others......like CPH... and 1/3 of BOT, ESE......

2. With Fewer shares and low capital raising or issue risk for quite a while.....

3. Big global markets, and China waiting to catch on the trend. This is the Blackmores of Dermatology.

4. European MM market now well covered with US$8bn pharma company....and innovative cannabanoid derm products....

5. Top class management including nominee for Telstra Business Woman of Year and ex Bellamys International Head of Sales for Asia.


Alot of boxes ticked.....so is a a 50%+ uplift ...really that hard to fathom ??

If we can break our capper at 32-33c....I think it will run towards my Short term momentum target of 50c

AIMHO. DYOR.

GG